Severe and prolonged neutropenia is a common consequence of cancer chemotherapy and is associated with an increased risk of severe infections. Transfusion of donor neutrophils is a viable option to combat this, but obtaining matched donors is a dilemma. There are pharmacologic interventions aimed at shortening the duration of neutropenia and combatting infection; however, infection risk remains high due to a lack of response to these treatments in many patients.
White blood cells play key roles in the body’s defense against disease-causing agents. One type of white blood cell, granulocytes, plays an important role in inflammation. It is known that inflammation influences cancer development and spread (metastasis). Neutrophils, the most abundant of the granulocytes, respond to messages released by tumor cells and affect the tumor growth process.
The cartilage in rheumatoid arthritis patients, once believed impenetrable to therapies, could be treated by the body's microvesicles that may carry therapeutic agents and enter these hard-to-reach spots.
Rheumatoid arthritis is an inflammatory autoimmune disease in which the body's own immune system attacks the joints and affects the underlying bone and cartilage, resulting in pain and inflammation. The disease may also affect other parts of the body, bringing serious complications such as low red blood cell count and inflammation around the heart. Between 0.5 and 1% of adults in the developed world are affected by rheumatoid arthritis, and the numbers are certain to grow as the population ages.
Mesenchymal stem cells therapy is raved as being the champion of immune modulators. Can the promise be realized?